Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
World Cancer Day – Shine a Light on the World
In 2018, it was estimated that 1,735,350 new cancer cases would be diagnosed in the United States and 609,640 individuals would pass from the disease [Cancer.gov]. We cannot sit by and ignore this life altering disease, which is why World Cancer Day, recognized on Feb. 4, is such an important awareness campaign to the Arfinn…
Read More 
REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals
Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More 
New study finds cannabis effective for treating migraines
A study published last month in the Journal of Pain found a statistically significant reduction in migraine and headache symptoms and recurrences among patients who used cannabis for treatment.Smoking cannabis reduced the severity and length of migraine episodes by nearly half. Researchers concluded that headache and migraine severity were reduced by nearly 50% after using cannabis. The study, conducted by researchers…
Read More 
State Board of Health reviews timelines for establishing Mississippi medical marijuana program
JACKSON, Miss. (WLBT) – The blueprint for Mississippi’s medical marijuana program is Initiative 65 that voters approved in November. That contains detailed requirements and the clock is ticking to get it started. The State Board of Health met virtually Wednesday to discuss the groundwork of the medical marijuana program. “I do want to tell you…
Read More 
Norfolk research company plans clinical trials using medical marijuana
Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More